Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forrester

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

Prostate cancer is often symptomless and is the second most common cancer in men globally

- PMLiVE

Cancer Research Horizons and the Karolinska Institutet announce five-year strategic partnership

The collaboration will aim to accelerate the translation of cancer research into clinical practice

- PMLiVE

AstraZeneca to acquire Neogene Therapeutics in $320m deal

The agreement will build the company’s pipeline of cell-based cancer treatments

- PMLiVE

AstraZeneca and C4X Discovery sign exclusive $403m licensing deal

The collaboration aims to develop an oral therapy for inflammatory and respiratory diseases

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation for children five to 11 years

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

ICR calls for further discussions following NICE’s rejection of breast cancer drug

Olaparib has been shown to cut the risk of cancer recurrence and improve survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links